Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joan Merrill

Rheumatology Oklahoma City, OK Medical Doctor

NPI 1962471813 CMS profile 43132

825 Ne 13Th St, Omrf E110, Oklahoma City, OK 73104

Open in the dashboard

General payments

$864,398

230 records reported · program years 2019–2025

Research payments

$516,641

Paid to them · 114 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$945,684 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Joan Merrill of Oklahoma City, OK is reported in the CMS Open Payments database as having received $864,398 across 230 general payments and $516,641 in research payments paid to them. Separately, studies naming them as principal investigator received $945,684 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $141,319 37
2025 Research $12,263 8
2024 General $104,893 44
2024 Research $77,625 6
2023 General $264,988 52
2023 Research $83,948 47
2022 General $70,593 22
2022 Research $174,250 7
2021 General $115,370 20
2021 Research $86,250 7
2020 General $97,523 20
2020 Research $58,509 13
2019 General $69,712 35
2019 Research $23,796 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joan Merrill
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Joan Merrill were reported at $141,319. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Joan Merrill Rheumatology median Middle half National median
2019 $69,712 $744 $153–$2,687 $163
2020 $97,523 $462 $98–$2,027 $114
2021 $115,370 $531 $101–$2,153 $132
2022 $70,593 $627 $125–$2,303 $149
2023 $264,988 $741 $145–$2,524 $160
2024 $104,893 $830 $166–$2,660 $164
2025 $141,319 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $204,334 19 payments
  2. Merck Sharp & Dohme Corporation $124,826 50 payments
  3. E.R. Squibb & Sons, L.L.C. $86,799 38 payments
  4. Sanofi US Services Inc. $85,923 11 payments
  5. Celgene Corporation $68,424 12 payments
  6. AbbVie, Inc. $66,585 32 payments
  7. EMD Serono, Inc. $60,193 9 payments
  8. EMD Serono Research & Development Institute, Inc. $54,450 2 payments
  9. Ucb SA $48,921 12 payments
  10. Sanofi-Aventis U.S. LLC $14,488 3 payments
  11. Other $49,455 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $840,854 165 payments
  2. Travel and Lodging $16,542 24 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,975 1 payment
  4. Honoraria $2,000 1 payment
  5. Food and Beverage $1,972 38 payments
  6. Education $55 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $49,015 12 payments
  2. SOTYKTU $44,775 11 payments
  3. BENLYSTA $7,854 4 payments
  4. ORENCIA $5,802 10 payments
  5. STELARA $4,197 4 payments
  6. LUPKYNIS $2,000 1 payment
  7. GAZYVA $1,150 1 payment
  8. Ultomiris $840 1 payment
  9. CC-220 $500 1 payment
  10. Enbrel $134 2 payments
  11. Other $116 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $285,857 90 payments
  2. EMD Serono Research & Development Institute, Inc. $110,925 8 payments
  3. Amgen Inc. $97,875 2 payments
  4. Sanofi US Services Inc. $16,635 11 payments
  5. EMD Serono, Inc. $4,500 1 payment
  6. Eli Lilly and Company $700 1 payment
  7. Celgene Corporation $150 1 payment

Records

344 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record